4-ethyl-1-benzyl-1H-1,2,3-triazole | 1332941-36-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-ethyl-1-benzyl-1H-1,2,3-triazole
• 英文别名: 1-Benzyl-4-ethyltriazole
• CAS: 1332941-36-2
• 化学式: C₁₁H₁₃N₃
• 分子量: 187.244
• InChiKey: WVTTUJWAESIRTE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  30.7
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  silver butynylide 、 苄基叠氮 在 吡啶 、 1,10-菲罗啉 、 tetrakis(actonitrile)copper(I) hexafluorophosphate 作用下， 反应 24.0h， 以71%的产率得到4-ethyl-1-benzyl-1H-1,2,3-triazole
  参考文献：
  名称：

  铜（i）催化的乙炔银和叠氮化物的环加成反应：将挥发性乙炔掺入三唑核中†

  摘要：

  乙炔银和有机叠氮化物在铜（I）催化下反应，得到1,4-二取代的1,2,3-三唑。机理研究表明，在环加成反应之前，需要先进行金属过渡成乙炔铜的过程。这项工作表明，乙炔化银可用作进入铜介导的偶联反应的合适前体。该方法允许将挥发性和难于处理的乙炔掺入三唑核中。

  DOI：

  10.1039/c1ob05360d

文献信息

• 3-METHYLIDENEOXAN-4-ONE COMPOUNDS AND SUBSTITUTED DERIVATIVES THEREOF AS INHIBITORS OF TELOMERASE
  申请人：NORTHWESTERN UNIVERSITY

  公开号：US20210070725A1

  公开（公告）日：2021-03-11

  Disclosed are 3-methylideneoxan-4-one compounds, derivatives thereof, and methods of their synthesis and methods of their use in treating a disease or disorder in a subject in need thereof, such as diseases and disorders that are associated with telomerase activity such as cancer. The disclosed compounds may be formulated in a pharmaceutical composition for treating diseases and disorders that are associated with telomerase activity such as cancer.

  本文披露了3-甲基亚氧杂环丙烯-4-酮化合物及其衍生物，以及它们的合成方法和在治疗患有疾病或障碍的受试者中的使用方法，例如与端粒酶活性相关的疾病和障碍，如癌症。披露的化合物可以制成药物组合物，用于治疗与端粒酶活性相关的疾病和障碍，如癌症。
• 3-methylideneoxan-4-one compounds and substituted derivatives thereof as inhibitors of telomerase
  申请人：NORTHWESTERN UNIVERSITY

  公开号：US11518750B2

  公开（公告）日：2022-12-06

  Disclosed are 3-methylideneoxan-4-one compounds, derivatives thereof, and methods of their synthesis and methods of their use in treating a disease or disorder in a subject in need thereof, such as diseases and disorders that are associated with telomerase activity such as cancer. The disclosed compounds may be formulated in a pharmaceutical composition for treating diseases and disorders that are associated with telomerase activity such as cancer.

  本发明公开了3-亚甲基氧杂环己烷-4-酮化合物、其衍生物及其合成方法和用于治疗有需要的受试者的疾病或失调的方法，例如与端粒酶活性相关的疾病和失调，如癌症。所公开的化合物可配制成药物组合物，用于治疗与端粒酶活性相关的疾病和紊乱，如癌症。
• MEDICAMENT FOR SUPPRESSING MALIGNANT TUMOR METASTASIS
  申请人：NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER

  公开号：US20170014419A1

  公开（公告）日：2017-01-19

  Provided are a novel medicament for suppressing or preventing the metastasis of a malignant tumor such as carcinoma, a novel treatment or prevention method for suppressing or preventing the metastasis of a malignant tumor, etc. The medicament comprises a non-peptidic angiotensin type 2 receptor agonist as an active ingredient. In the medicament, the non-peptidic angiotensin type 2 receptor agonist may be, for example, a sulfonyl malonamide compound. The medicament may be a medicament for use in combination with an anticancer agent and/or an antitumor agent.
• US8461209B2
  申请人：——

  公开号：US8461209B2

  公开（公告）日：2013-06-11
• US9040715B2
  申请人：——

  公开号：US9040715B2

  公开（公告）日：2015-05-26